1. Home
  2. KOP vs YMAB Comparison

KOP vs YMAB Comparison

Compare KOP & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KOP
  • YMAB
  • Stock Information
  • Founded
  • KOP 1988
  • YMAB 2015
  • Country
  • KOP United States
  • YMAB United States
  • Employees
  • KOP N/A
  • YMAB N/A
  • Industry
  • KOP Forest Products
  • YMAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • KOP Basic Materials
  • YMAB Health Care
  • Exchange
  • KOP Nasdaq
  • YMAB Nasdaq
  • Market Cap
  • KOP 784.2M
  • YMAB 631.1M
  • IPO Year
  • KOP 2006
  • YMAB 2018
  • Fundamental
  • Price
  • KOP $36.50
  • YMAB $11.14
  • Analyst Decision
  • KOP Buy
  • YMAB Strong Buy
  • Analyst Count
  • KOP 1
  • YMAB 8
  • Target Price
  • KOP $64.00
  • YMAB $21.38
  • AVG Volume (30 Days)
  • KOP 107.6K
  • YMAB 268.9K
  • Earning Date
  • KOP 11-08-2024
  • YMAB 11-08-2024
  • Dividend Yield
  • KOP 0.77%
  • YMAB N/A
  • EPS Growth
  • KOP N/A
  • YMAB N/A
  • EPS
  • KOP 3.52
  • YMAB N/A
  • Revenue
  • KOP $2,128,300,000.00
  • YMAB $84,553,000.00
  • Revenue This Year
  • KOP $2.08
  • YMAB $10.24
  • Revenue Next Year
  • KOP $3.37
  • YMAB $20.21
  • P/E Ratio
  • KOP $10.36
  • YMAB N/A
  • Revenue Growth
  • KOP 0.22
  • YMAB N/A
  • 52 Week Low
  • KOP $33.80
  • YMAB $5.17
  • 52 Week High
  • KOP $58.23
  • YMAB $20.90
  • Technical
  • Relative Strength Index (RSI)
  • KOP 49.84
  • YMAB 25.01
  • Support Level
  • KOP $36.98
  • YMAB $12.47
  • Resistance Level
  • KOP $38.44
  • YMAB $15.69
  • Average True Range (ATR)
  • KOP 1.22
  • YMAB 0.97
  • MACD
  • KOP 0.22
  • YMAB -0.46
  • Stochastic Oscillator
  • KOP 44.03
  • YMAB 9.88

About KOP Koppers Holdings Inc.

Koppers Holdings, through its subsidiaries, manufactures and sells wood products, wood treatment chemicals, and carbon compounds used in markets such as railroad, aluminum and steel, agriculture, utilities, and residential lumber. The company is organized into three business segments: railroad and utility products and services, performance chemicals, and carbon materials and chemicals. Its product portfolio includes treated and untreated wood products like crossties used in railroads, wood preservation chemicals, and carbon compounds such as creosote used in the treatment of wood crossties, among others. The majority of its revenue comes from the company's railroad and utility products and services segment, and more than half of the company's revenue is earned in the United States.

About YMAB Y-mAbs Therapeutics Inc.

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

Share on Social Networks: